STOCK TITAN

Calumet, Inc. (CLMT) Financials

CLMT
Trailing 12 months to June 30, 2026
Revenue $4.6B YoY not available
Net Income -$136.8M YoY not available
EPS (Diluted) -$1.55 +70.2% YoY
Free Cash Flow $58.4M +144.6% YoY
Market Cap $5.0B as of Sep 11, 2026
Price / Sales 1.1x on $4.6B revenue, trailing 12 months to June 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLMT SEC filings page.

Calumet, Inc. (CLMT) reported $4.6B in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLMT FY2025

Cash recovery depends on lighter reinvestment, while Calumet’s liability-heavy balance sheet remains the dominant business mechanic.

After negative FCF in FY2024, FY2025 produced operating cash flow of $108.9M and FCF of $56.6M, showing that the earnings recovery reached cash generation. The cash-conversion shift also coincided with capex falling to $52.3M from $76.7M, so lighter reinvestment—not just improved operations—helped create the cash inflection.

Operating margin expanded from 0.2% in FY2024 to 2.6% in FY2025. With revenue staying near $4.1B, this is margin recovery without volume expansion, pointing to better economics per dollar rather than sales scale.

The current ratio improved to 1.0x in FY2025, but equity remained negative at -$732.7M; short-term coverage improved without repairing the long-term capital deficit. Long-term debt of $2.1B within total liabilities of $3.2B shows that financing claims remain central even as cash generation turned positive.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 28 / 100
Financial Health Score 28/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Calumet, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
40

Calumet, Inc. has an operating margin of 2.6%, meaning the company retains $3 of operating profit per $100 of revenue. This results in a moderate score of 40/100, indicating healthy but not exceptional operating efficiency. This is up from 0.2% the prior year.

Growth
29

Calumet, Inc.'s revenue declined 1.2% year-over-year, from $4.2B to $4.1B. This contraction results in a growth score of 29/100.

Leverage
7
Liquidity
19

Calumet, Inc.'s current ratio of 1.02 is below the typical benchmark, resulting in a score of 19/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow
22

Calumet, Inc.'s free cash flow margin of 1.4% results in a low score of 22/100. Capital expenditures of $52.3M absorb a large share of operating cash flow.

Returns
48
Altman Z-Score Distress
1.80

Calumet, Inc. scores 1.80, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.0B) relative to total liabilities ($3.2B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
6/9

Calumet, Inc. passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed
N/A

Calumet, Inc. reported a net loss of $33.8M while generating $108.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
0.50x

Calumet, Inc. earns $0.50 in operating income for every $1 of interest expense ($108.7M vs $215.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$1.4B
YoY+40.8%
QoQ+40.3%

Calumet, Inc. generated $1.4B in revenue in Q2 2026. This represents an increase of 40.8% from the same quarter a year earlier. Against the prior quarter it is up 40.3%.

EBITDA
$5.5M
YoY+110.4%
QoQ+104.0%

Calumet, Inc.'s EBITDA was $5.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 110.4% from the same quarter a year earlier. Against the prior quarter it is up 104.0%.

Net Income
-$95.9M
YoY+35.2%
QoQ+69.7%

Calumet, Inc. reported -$95.9M in net income in Q2 2026. This represents an increase of 35.2% from the same quarter a year earlier. Against the prior quarter it is up 69.7%.

EPS (Diluted)
-$1.09
YoY+35.9%
QoQ+70.1%

Calumet, Inc. earned -$1.09 per diluted share (EPS) in Q2 2026. This represents an increase of 35.9% from the same quarter a year earlier. Against the prior quarter it is up 70.1%.

Cash & Balance Sheet

Free Cash Flow
$54.0M
YoY+359.6%
QoQ+154.3%

Calumet, Inc. generated $54.0M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 359.6% from the same quarter a year earlier. Against the prior quarter it is up 154.3%.

Cash & Debt
$109.8M
YoY-0.7%
QoQ-20.8%

Calumet, Inc. held $109.8M in cash against $2.2B in long-term debt as of Q2 2026.

Shares Outstanding
88M
YoY+1.3%
QoQ+0.9%

Calumet, Inc. had 88M shares outstanding in Q2 2026. This represents an increase of 1.3% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin
1.3%
YoY+5.5pp
QoQ+9.8pp

Calumet, Inc.'s gross margin was 1.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.8 percentage points.

Operating Margin
-2.8%
YoY+7.1pp
QoQ+13.9pp

Calumet, Inc.'s operating margin was -2.8% in Q2 2026, reflecting core business profitability. This is up 7.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.9 percentage points.

Net Margin
-6.6%
YoY+7.8pp
QoQ+24.1pp

Calumet, Inc.'s net profit margin was -6.6% in Q2 2026, showing the share of revenue converted to profit. This is up 7.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 24.1 percentage points.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

Capital Expenditures
$38.3M
YoY+101.6%
QoQ+190.2%

Calumet, Inc. invested $38.3M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 101.6% from the same quarter a year earlier. Against the prior quarter it is up 190.2%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

CLMT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLMT quarterly income statement
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Revenue$1.4B+40.8%$1.0B+3.6%$1.0B$1.1B-2.0%$1.0B$993.9M-1.2%N/A$1.1B-4.3%
Cost of Revenue$1.4B+33.3%$1.1B+3.9%$1.0B$704.3M-35.7%$1.1B$1.1B+16.0%N/A$1.1B+23.4%
Gross Profit$18.3M+142.0%-$87.5M-7.5%-$3.0M$373.7M+7526.5%-$43.6M-$81.4M-203.7%N/A$4.9M-98.1%
SG&A Expenses$39.4M-4.1%$66.0M+445.5%$39.2M$31.4M-21.9%$41.1M$12.1M-48.1%N/A$40.2M0.0%
Operating Income-$40.0M+60.4%-$171.3M-251.7%-$64.5M$322.9M+665.5%-$101.0M-$48.7M-234.2%N/A-$57.1M-126.8%
EBITDA$5.5M+110.4%-$138.3M-1082.1%-$51.3M$373.6M+3266.1%-$53.1M-$11.7M-114.3%N/A-$11.8M-104.6%
Interest Expense$52.0M-1.7%$51.1M-12.6%$50.8M$53.6M-7.1%$52.9M$58.5M-3.8%N/A$57.7M-1.7%
Income Tax-$21.2M-10700.0%-$20.8M-5300.0%-$51.8M-$41.4M-6014.3%$200K$400K+100.0%N/A$700K+40.0%
Net Income-$95.9M+35.2%-$317.0M-95.7%-$37.3M$313.4M+411.5%-$147.9M-$162.0M-289.4%N/A-$100.6M-200.8%
EPS (Basic)-$1.09+35.9%-$3.64-94.7%-$0.43+6.5%$3.61+405.9%-$1.70-254.2%-$1.87-266.7%-$0.46-$1.18-195.2%
EPS (Diluted)-$1.09+35.9%-$3.64-94.7%-$0.43+6.5%$3.61+405.9%-$1.70-254.2%-$1.87-266.7%-$0.46-$1.18-195.2%
Diluted Shares (Avg)88M+0.9%87M+0.7%N/A87M+1.6%87M+7.7%86M+7.6%N/A86M+6.4%

Not reported in any period shown, so not listed: R&D Expenses.

CLMT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLMT quarterly balance sheet
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Total Assets$2.8B+1.0%$2.8B-2.4%$2.7B-2.5%$2.7B+3.6%$2.8B+2776399900.0%$2.8B$2.8B+0.3%$2.6B
Current Assets$1.0B+14.2%$927.9M+1.1%$857.8M+12.0%$880.1M+11.4%$895.8M+895799900.0%$917.9M$766.0M-3.6%$789.8M
Cash & Equivalents$109.8M-0.7%$138.6M+12.3%$125.1M+228.3%$94.6M+173.4%$110.6M$123.4M+416.3%$38.1M+382.3%$34.6M+152.6%
Short-Term Investments$0$0$0$0$0$0$0$0
Inventory$421.0M+13.6%$369.5M-5.1%$385.2M-7.5%$400.1M-2.3%$370.5M$389.4M$416.3M-5.3%$409.5M
Accounts Receivable$417.0M+53.8%$358.4M+27.4%$224.4M-7.2%$263.9M-5.6%$271.1M$281.4M$241.7M-4.2%$279.6M
Long-Term Investments$0$0$0$0$0$0$0$0
GoodwillN/AN/A$140.5M-18.8%N/AN/AN/A$173.0M0.0%N/A
Total Liabilities$3.7B+4.2%$3.5B+3.1%$3.2B-1.5%$3.2B+3.8%$3.5B+525.1%$3.4B$3.2B+7.6%$3.1B
Current Liabilities$1.2B+3.5%$963.1M+10.8%$840.7M-2.7%$776.3M-38.1%$1.2B$869.1M$863.6M-22.4%$1.3B
Non-Current Liabilities$2.5B+4.6%$2.6B+0.5%$2.3B-1.1%$2.4B+32.8%$2.4B$2.6B$2.4B+25.4%$1.8B
Long-Term Debt$2.2B+5.7%$2.3B-0.1%$2.1B+0.6%$2.1B+29.4%$2.1B$2.3B$2.1B+12.8%$1.7B
Total Equity-$1.1B-12.6%-$1.0B-21.0%-$732.7M-2.9%-$695.3M-3.4%-$1.0B-78.3%-$862.3M-62.8%-$711.9M-45.2%-$672.2M-51.7%
Retained Earnings-$2.0B-7.4%-$1.9B-11.1%-$1.6B-2.2%-$1.5B+29.0%-$1.8B-$1.7B-$1.5B+22.4%-$2.2B

CLMT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLMT quarterly cash flow statement
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Operating Cash Flow$92.3M+5227.8%-$86.2M-194.2%$116.5M+3526.5%$23.5M+251.6%-$1.8M-$29.3M+68.8%-$3.4M+54.7%-$15.5M
Depreciation & Amortization$45.5M-5.0%$33.0M-10.8%$13.2M$50.7M+11.9%$47.9M$37.0M-18.5%N/A$45.3M+3.9%
Stock-Based CompensationN/A$37.4M+274.0%N/AN/AN/A-$21.5MN/AN/A
Capital Expenditures$38.3M+101.6%$13.2M-25.0%$12.7M-49.2%$23.5M+21.1%$19.0M$17.6M-12.0%$25.0M-20.6%$19.4M-59.6%
Free Cash Flow$54.0M+359.6%-$99.4M-111.9%$103.8M+465.5%$0+100.0%-$20.8M-$46.9M+58.9%-$28.4M+27.2%-$34.9M
Investing Cash Flow-$39.3M-189.0%-$13.7M-117.6%-$11.7M+53.2%-$8.4M+49.7%-$13.6M$77.8M+489.0%-$25.0M+20.6%-$16.7M
Financing Cash Flow-$81.8M-3246.2%$73.4M-32.7%-$74.3M-332.2%-$31.1M-151.9%$2.6M$109.0M-16.6%$32.0M-3.9%$59.9M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CLMT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLMT quarterly financial ratios
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Gross Margin1.3%+5.5pp-8.5%-0.3pp-0.3%34.7%+34.2pp-4.3%-8.2%-16.0ppN/A0.4%-22.3pp
Operating Margin-2.8%+7.1pp-16.6%-11.7pp-6.2%29.9%+35.1pp-9.8%-4.9%-8.5ppN/A-5.2%-23.7pp
Net Margin-6.6%+7.8pp-30.8%-14.5pp-3.6%29.1%+38.2pp-14.4%-16.3%-12.2ppN/A-9.1%-17.8pp
Return on Assets-3.4%+1.9pp-11.5%-5.8pp-1.4%11.5%+15.3pp-5.3%-5.7%N/A-3.8%
Current Ratio0.84+0.1x0.96-0.1x1.02+0.1x1.13+0.5x0.761.060.89+0.2x0.63
Asset Turnover0.52+0.1x0.370.0x0.390.390.0x0.370.35N/A0.42
FCF Margin3.7%+5.8pp-9.7%-4.9pp10.0%0.0%+3.2pp-2.0%-4.7%+6.6ppN/A-3.2%

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Note: Shareholder equity is negative (-$732.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Calumet, Inc. CLMT FY2025 $4.1B -$33.8M -0.8% $5.0B 28/100
Stepan SCL FY2025 $2.3B $46.9M 2.0% $1.4B 39/100
Ecovyst Inc ECVT FY2025 $723.5M -$71.1M -9.8% $1.1B 65/100
Oil-Dri Corporation of America ODC FY2025 $485.6M $54.0M 11.1% $1.2B 66/100
Kronos Worldwide Inc KRO FY2025 $1.9B -$110.9M -6.0% $973.7M 36/100

Frequently Asked Questions

What is Calumet, Inc.'s annual revenue?

Calumet, Inc. (CLMT) reported $4.1B in total revenue for fiscal year 2025. This represents a -1.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Calumet, Inc.'s revenue growing?

Calumet, Inc. (CLMT) revenue declined by 1.2% year-over-year, from $4.2B to $4.1B in fiscal year 2025.

Is Calumet, Inc. profitable?

No, Calumet, Inc. (CLMT) reported a net income of -$33.8M in fiscal year 2025, with a net profit margin of -0.8%.

Calumet, Inc. (CLMT) reported diluted earnings per share of -$0.39 for fiscal year 2025. This represents a 85.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Calumet, Inc. (CLMT) had EBITDA of $257.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Calumet, Inc. (CLMT) had $125.1M in cash and equivalents against $2.1B in long-term debt.

Calumet, Inc. (CLMT) had a gross margin of 5.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Calumet, Inc. (CLMT) had an operating margin of 2.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Calumet, Inc. (CLMT) had a net profit margin of -0.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Calumet, Inc. (CLMT) generated $56.6M in free cash flow during fiscal year 2025. This represents a 146.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Calumet, Inc. (CLMT) generated $108.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Calumet, Inc. (CLMT) had $2.7B in total assets as of fiscal year 2025, including both current and long-term assets.

Calumet, Inc. (CLMT) invested $52.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Calumet, Inc. (CLMT) had 87M shares outstanding as of fiscal year 2025.

Calumet, Inc. (CLMT) had a current ratio of 1.02 as of fiscal year 2025, which is considered adequate.

Calumet, Inc. (CLMT) had a return on assets of -1.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Calumet, Inc. (CLMT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $5.0B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Calumet, Inc. (CLMT) trades at 1.1x sales, its market capitalization divided by revenue of $4.6B revenue, trailing 12 months to June 30, 2026. The market capitalization is $5.0B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Calumet, Inc. (CLMT) has negative shareholder equity of -$732.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Calumet, Inc. (CLMT) has an Altman Z-Score of 1.80, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Calumet, Inc. (CLMT) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Calumet, Inc. (CLMT) reported a net loss of $33.8M while generating $108.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Calumet, Inc. (CLMT) has an interest coverage ratio of 0.50x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Calumet, Inc. (CLMT) scores 28 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top